Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 4/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9273082 | 0.83 | MEN1 (0.58) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL6940992 | 0.81 | ALDH1A1 (0.63) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL31240530 | 0.81 | ALDH1A1 (0.63) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL5457127 | 0.79 | NCEH1 (0.42) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL27717730 | 0.75 | ALDH1A1 (0.55) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL10829102 | 0.74 | NCEH1 (0.33) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL1694540 | 0.73 | MEN1 (0.68) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL10771128 | 0.72 | ALDH1A1 (0.47) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL28284977 | 0.72 | CA12 (0.49) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL28207840 | 0.71 | ALDH1A1 (0.50) | ALDH1A1HPGDMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438106-B1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | BOEING CO (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2438106-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | The Boeing Company (US) | 2012-04-11 | — | — | EP | disclosed |
| US-8106142-B2 | Polyacetylinic oligomers | THE BOEING COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8063168-B2 | Oligomers with di-phenylethynyl endcaps | THE BOEING COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010141106-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | THE BOEING COMPANY (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100204412-A1 | OLIGOMERS WITH DI-PHENYLETHYNYL ENDCAPS | THE BOEING COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204485-A1 | POLYACETYLINIC OLIGOMERS | THE BOEING COMPANY | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204485-A1 | POLYACETYLINIC OLIGOMERS | AADAC, ACMSD, ECPAS | ALDH1A1 495/4885HPGD 1829/4885MEN1 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.